Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
NCT00051909
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
LY451395
Sponsor
Eli Lilly and Company